MedTrace Logo

Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

NCT00005980 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2012-07-18

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of liposomal doxorubicin is more effective for metastatic breast cancer.

PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of liposomal doxorubicin in treating women who have metastatic breast cancer.

Conditions

Interventions

DRUG

pegylated liposomal doxorubicin hydrochloride

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Robert E. Coleman, MD, FRCP · Cancer Research Centre at Weston Park Hospital

  • Maurizio D'Incalci, MD · Mario Negri Institute for Pharmacological Research

  • Christian Dittrich, MD · Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Primary Completion
2002-07-31

Countries

  • Austria
  • France
  • Greece
  • Israel
  • Italy
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005980 on ClinicalTrials.gov